The Bladder Cancer Company

About Us

Our Values

Our History

Bladder cancer challenge

Board of directors

Executive Leadership

Leadership

Our Company

Precision Diagnostics

Our products

Research support

Innovation & Products

News

The Importance of Health Economics​

Bladder Cancer and AI

Addressing Inequality

Our Perspective

Patient Registries And Real-World Evidence

Bladder cancer community support

Corporate social responsibility

ESG Report

Our Impact

Why Partner with Photocure

Our Partners

Partners

Photocure culture

Working at Photocure

Careers

Contact

Events & Presentations

Financials

Shareholder information

FAQs

Investors hub

Investors

Press & Media

Privacy Policy

Terms of use

cevira

New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Medical Information

New publication: examining 12-months recurrence-free survival following photo coagulation of bladder tumor versus TUR-BT 

The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Medical congresses & events

Organisational Announcements

Photocure receives prestigious Innovation Prize from the Norwegian Cancer Society: Recognition for Groundbreaking Contributions in Bladder Cancer Diagnostics

New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Photocure ASA: Notification of primary insider transaction

Financial Investment & Stock

Photocure ASA: Results for the third quarter of 2025

Photocure ASA: Invitation to presentation of third quarter 2025 financial results

Partnership News & Expansion

Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy

Photocure Partner Asieris publishes Phase III Results from the APRICITY Study for Cevira (APL-1702) in Med journal 

Photocure ASA - Share option grant

Photocure raises awareness at EU Roundtable and Report on bladder cancer

Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review

Photocure ASA: Results for the second quarter of 2025

Photocure ASA: Invitation to presentation of second quarter and first half year 2025 financial results

Photocure starts up commercial operations in Spain

Patient Registries

Real World Evidence

New publication: Higher level of use of BLC improves bladder cancer patient outcomes

Asieris will present Cevira trial data and showcase Hexvix at the IPA congress

Photocure ASA: Results for the first quarter of 2025

Photocure ASA: Annual general meeting held

Photocure ASA: Invitation to presentation of first quarter 2025 financial results

Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making

Photocure ASA - Notice of the Annual General Meeting 5 May 2025

Photocure ASA: Annual Report 2024

Photocure ASA: Transactions made under share buyback program

Photocure ASA - Share option grant to Vice President and General Manager EMEA

Photocure appoints Jane Healy as Vice President and General Manager EMEA

Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer

Photocure ASA: Initiation of a share buyback

New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk of Bladder Cancer Recurrence

Photocure ASA: Results for the fourth quarter of 2024

Product Announcements

News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared

Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2024 financial results

Photocure Partner Asieris awarded "Annual Star of Innovation" with Hexvix at the 5th Annual Lunjian Awards 2024

Photocure ASA: Results for the third quarter of 2024

Cevira in Cervical HSIL: Asieris Announces Presentation of Data at the 2024 IPVC Conference Highlighting the Clearance Rate for Different HPV Types 

Photocure ASA: Invitation to presentation of third quarter 2024 financial results

Photocure Partner Asieris announces Marketing Approval by the National Medical Products Administration for Hexvix in China

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting

Photocure establishes Named Patient Program to provide access to Hexvix in South Africa

Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference

New publication: blue light cystoscopy shows potential to facilitate the diagnosis of CIS in the upper urinary tract

Photocure ASA: Results for the second quarter of 2024

Photocure ASA: Invitation to presentation of second quarter and first half year 2024 financial results

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

New Photocure White Paper:  Beyond the buzzwords – How AI and advancing diagnostic technologies will transform early bladder cancer care

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Photocure ASA – Annual general meeting held

Photocure ASA: Results for the first quarter of 2024

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Photocure ASA: Invitation to presentation of first quarter 2024 financial results

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Photocure ASA – Notice of the Annual General Meeting 23 May 2024

Photocure ASA: Annual Report 2023

Bladder Cancer: pivotal trial results and new real-world evidence, to be presented at AUA 2024, demonstrate improved diagnostic and clinical outcomes with blue light cystoscopy

Photocure ASA – Share option grant

European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care

Investor conferences

Photocure to Participate in the 23[rd] Annual Needham Virtual Healthcare Conference

EAU 2024: Photocure Partner Asieris to present the Drug and Equipment Performance Results from the Chinese Phase III Clinical Study of Hexvix in Combination with HD 4K Blue Light Cystoscopy equipment

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Canadian Health Authorities approve updated and expanded label for Cysview

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

Photocure Partner Asieris to Unveil Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 SGO

Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

Photocure ASA: Results for the fourth quarter of 2023

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results

New Photocure White Paper addressing Inequality in Bladder Cancer Care and the importance of Real World Evidence

Photocure Partner Asieris presented clinical trial and real-world data on Hexvix in China at ASCO GU 2024

Photocure Partner Asieris to present unpublished clinical trial and real-world data on Hexvix in China at ASCO GU 2024

SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Photocure to present at four investor conferences in November/December 2023

Photocure ASA: Results for the third quarter of 2023

New publication: immunological impact of Blue Light Cystoscopy with hexaminolevulinate in bladder cancer

Photocure ASA: Invitation to presentation of third quarter 2023 financial results

Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress

Photocure Partner Asieris to present first results for its Hexvix Phase III clinical trial in China at the SIU 2023 Annual Meeting

New Health Economic analysis in France concludes there is insignificant cost difference between White Light and Blue Light Cystoscopy use when applying ccAFU guidelines

Photocure ASA: Change of Board Composition

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Photocure Bladder Cancer Roadshow in Germany & Austria: 2nd edition informs patients and professionals

Photocure Partner Asieris confirms Hexvix Phase III clinical trial in China meets endpoint

Photocure ASA: Results for the second quarter and first half of 2023

Photocure ASA: Invitation to presentation of second quarter and first half year 2023 financial results

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

New publication reinforces the clinical benefits of Blue Light Cystoscopy demonstrating an improvement in detection of CIS

Photocure ASA: Results for the first quarter of 2023

<p>We use cookies to provide the best possible experience for you. By closing this message you agree to our use of cookies. You can learn more about cookies on our <a href="https://photocure.com/privacy-policy" target="_blank" rel="noopener noreferrer">privacy page</a>.</p>

agree